Association of gut microbiota with COVID‐19 susceptibility and severity: A two‐sample Mendelian randomization study
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28734 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Weifeng Shang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, COVID-19, Microbiota. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Evidence supports the observational associations of gut microbiota with the risk of COVID‐19; however, it is unclear whether these associations reflect a causal relationship. This study investigated the association of gut microbiota with COVID‐19 susceptibility and severity. Data were obtained from a large‐scale gut microbiota data set ( n = 18 340) and the COVID‐19 Host Genetics Initiative ( n = 2 942 817). Causal effects were estimated with inverse variance weighted (IVW), MR‐Egger, and weighted median, and sensitivity analyses were implemented with Cochran's Q test, MR‐Egger intercept test, MR‐PRESSO, leave‐one‐out analysis, and funnel plots. For COVID‐19 susceptibility, IVW estimates suggested that Gammaproteobacteria (odds ratio [OR] = 0.94, 95% confidence interval [CI], 0.89–0.99, p = 0.0295] and Streptococcaceae (OR = 0.95, 95% CI, 0.92–1.00, p = 0.0287) had a reduced risk, while Negativicutes (OR = 1.05, 95% CI, 1.01–1.10, p = 0.0302), Selenomonadales (OR = 1.05, 95% CI, 1.01–1.10, p = 0.0302), Bacteroides (OR = 1.06, 95% CI, 1.01–1.12, p = 0.0283), and Bacteroidaceae (OR = 1.06, 95% CI, 1.01–1.12, p = 0.0283) were associated with an increased risk (all p < 0.05, nominally significant). For COVID‐19 severity, Subdoligranulum (OR = 0.80, 95% CI, 0.69–0.92, p = 0.0018), Cyanobacteria (OR = 0.85, 95% CI, 0.76–0.96, p = 0.0062), Lactobacillales (OR = 0.87, 95% CI, 0.76–0.98, p = 0.0260), Christensenellaceae (OR = 0.87, 95% CI, 0.77–0.99, p = 0.0384), Tyzzerella3 (OR = 0.89, 95% CI, 0.81–0.97, p = 0.0070), and RuminococcaceaeUCG011 (OR = 0.91, 95% CI, 0.83–0.99, p = 0.0247) exhibited negative correlations, while RikenellaceaeRC9 (OR = 1.09, 95% CI, 1.01–1.17, p = 0.0277), LachnospiraceaeUCG008 (OR = 1.12, 95% CI, 1.00–1.26, p = 0.0432), and MollicutesRF9 (OR = 1.14, 95% CI, 1.01–1.29, p = 0.0354) exhibited positive correlations (all p < 0.05, nominally significant). Sensitivity analyses validated the robustness of the above associations. These findings suggest that gut microbiota might influence the susceptibility and severity of COVID‐19 in a causal way, thus providing novel insights into the gut microbiota‐mediated development mechanism of COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Anhui Medical University, Hefei, China.
ORCID-Profile: Dechang Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Shang, W., Zhang, S., Qian, H., Pan, X., Huang, S., Wen, Z., Liu, J., & Chen, D. (2023). Association of gut microbiota with COVID‐19 susceptibility and severity: A two‐sample Mendelian randomization study. Journal of Medical Virology. https://doi.org/10.1002/jmv.28734
Vancouver
Shang W, Zhang S, Qian H, Pan X, Huang S, Wen Z, et al. Association of gut microbiota with COVID‐19 susceptibility and severity: A two‐sample Mendelian randomization study. Journal of Medical Virology. 2023. doi:10.1002/jmv.28734
BibTeX
@article{Shang2023,
author = {Shang, Weifeng and Zhang, Sheng and Qian, Hang and Pan, Xiaojun and Huang, Sisi and Wen, Zhenliang and Liu, Jiao and Chen, Dechang},
title = {Association of gut microbiota with COVID‐19 susceptibility and severity: A two‐sample Mendelian randomization study},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28734}
}
EUVIMED